APM
ZNTL icon

Avidity Partners Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Avidity Partners Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,100,000
Closed -$42.1M – 91
2023
Q3 		$42.1M Sell
2,100,000
-234,000
-10% -$5.94M 1.7% 21
2023
Q2 		$65.8M Sell
2,334,000
-595,300
-20% -$14.3M 2.3% 11
2023
Q1 		$50.4M Sell
2,929,300
-2,220,700
-43% -$45M 1.67% 24
2022
Q4 		$104M Buy
5,150,000
+926,900
+22% +$19.9M 2.25% 15
2022
Q3 		$91.5M Buy
4,223,100
+637,219
+18% +$17.4M 1.86% 21
2022
Q2 		$101M Buy
3,585,881
+408,882
+13% +$10.8M 2.31% 19
2022
Q1 		$147M Buy
3,176,999
+461,999
+17% +$24.9M 3.05% 9
2021
Q4 		$228M Buy
2,715,000
+221,200
+9% +$17.1M 4.84% 2
2021
Q3 		$166M Buy
2,493,800
+333,800
+15% +$19.3M 3.68% 7
2021
Q2 		$115M Buy
2,160,000
+896,700
+71% +$48M 3.11% 7
2021
Q1 		$54.8M Buy
1,263,300
+128,300
+11% +$5.52M 1.51% 22
2020
Q4 		$59M Buy
1,135,000
+230,881
+26% +$10.4M 1.91% 14
2020
Q3 		$29.6M Buy
904,119
+229,632
+34% +$8.04M 1.37% 24
2020
Q2 		$32.4M Buy
+674,487
New +$25.9M 2.08% 17

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Avidity Partners Management's ZNTL Position: Q4 2023 in Review

Avidity Partners Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 2,100,000 shares — an estimated $42.1M sold.

Avidity Partners Management first reported a position in ZNTL in Q2 2020 and held it in 14 quarters. The position peaked at $228M in Q4 2021. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

  • Avidity Partners Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Avidity Partners Management sold 2,100,000 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $42.1M.
  • Avidity Partners Management first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 14 quarters.
  • Avidity Partners Management's Zentalis Pharmaceuticals position peaked at $228M in Q4 2021.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on Avidity Partners Management's 13F filing for Q4 2023, filed 14 Feb 2024.